within Pharmacolibrary.Drugs.ATC.N;

model N02AJ17
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.039,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 900,            
    Vdp             = 0.071,
    k12             = 5.1,
    k21             = 5.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AJ17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oxycodone and paracetamol is a fixed-dose combination medication used for the treatment of moderate to severe pain. Oxycodone is a semi-synthetic opioid analgesic, while paracetamol (acetaminophen) is a widely used non-opioid analgesic and antipyretic. The combination is approved and commonly prescribed for acute pain management in both inpatient and outpatient clinical settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from published studies in healthy adult subjects (mixed sex, age 18–55). Primarily based on single oral dose of oxycodone/paracetamol fixed-combination tablets.</p><h4>References</h4><ol><li><p>Thigpen, JC, et al., &amp; Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. <i>European journal of drug metabolism and pharmacokinetics</i> 44(5) 591–609. DOI:<a href=\"https://doi.org/10.1007/s13318-019-00552-0\">10.1007/s13318-019-00552-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31006834/\">https://pubmed.ncbi.nlm.nih.gov/31006834</a></p></li><li><p>Wiffen, PJ, et al., &amp; Moore, RA (2017). Opioids for cancer pain - an overview of Cochrane reviews. <i>The Cochrane database of systematic reviews</i> 7(7) CD012592–None. DOI:<a href=\"https://doi.org/10.1002/14651858.CD012592.pub2\">10.1002/14651858.CD012592.pub2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28683172/\">https://pubmed.ncbi.nlm.nih.gov/28683172</a></p></li><li><p>Ormrod, D, et al., &amp; Wagstaff, AJ (2002). Valdecoxib. <i>Drugs</i> 62(14) 2059–2073. DOI:<a href=\"https://doi.org/10.2165/00003495-200262140-00005\">10.2165/00003495-200262140-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12269850/\">https://pubmed.ncbi.nlm.nih.gov/12269850</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AJ17;
